These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 28237426)

  • 1. The Role of the Human Visual Cortex in Assessment of the Long-Term Durability of Retinal Gene Therapy in Follow-on RPE65 Clinical Trial Patients.
    Ashtari M; Nikonova ES; Marshall KA; Young GJ; Aravand P; Pan W; Ying GS; Willett AE; Mahmoudian M; Maguire AM; Bennett J
    Ophthalmology; 2017 Jun; 124(6):873-883. PubMed ID: 28237426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2.
    Testa F; Maguire AM; Rossi S; Pierce EA; Melillo P; Marshall K; Banfi S; Surace EM; Sun J; Acerra C; Wright JF; Wellman J; High KA; Auricchio A; Bennett J; Simonelli F
    Ophthalmology; 2013 Jun; 120(6):1283-91. PubMed ID: 23474247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years.
    Jacobson SG; Cideciyan AV; Ratnakaram R; Heon E; Schwartz SB; Roman AJ; Peden MC; Aleman TS; Boye SL; Sumaroka A; Conlon TJ; Calcedo R; Pang JJ; Erger KE; Olivares MB; Mullins CL; Swider M; Kaushal S; Feuer WJ; Iannaccone A; Fishman GA; Stone EM; Byrne BJ; Hauswirth WW
    Arch Ophthalmol; 2012 Jan; 130(1):9-24. PubMed ID: 21911650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Long-Term Efficacy of AAV4 Gene Therapy in Patients with RPE65 Leber Congenital Amaurosis.
    Le Meur G; Lebranchu P; Billaud F; Adjali O; Schmitt S; Bézieau S; Péréon Y; Valabregue R; Ivan C; Darmon C; Moullier P; Rolling F; Weber M
    Mol Ther; 2018 Jan; 26(1):256-268. PubMed ID: 29033008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results at 2 Years after Gene Therapy for RPE65-Deficient Leber Congenital Amaurosis and Severe Early-Childhood-Onset Retinal Dystrophy.
    Weleber RG; Pennesi ME; Wilson DJ; Kaushal S; Erker LR; Jensen L; McBride MT; Flotte TR; Humphries M; Calcedo R; Hauswirth WW; Chulay JD; Stout JT
    Ophthalmology; 2016 Jul; 123(7):1606-20. PubMed ID: 27102010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial.
    Bennett J; Wellman J; Marshall KA; McCague S; Ashtari M; DiStefano-Pappas J; Elci OU; Chung DC; Sun J; Wright JF; Cross DR; Aravand P; Cyckowski LL; Bennicelli JL; Mingozzi F; Auricchio A; Pierce EA; Ruggiero J; Leroy BP; Simonelli F; High KA; Maguire AM
    Lancet; 2016 Aug; 388(10045):661-72. PubMed ID: 27375040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The human visual cortex responds to gene therapy-mediated recovery of retinal function.
    Ashtari M; Cyckowski LL; Monroe JF; Marshall KA; Chung DC; Auricchio A; Simonelli F; Leroy BP; Maguire AM; Shindler KS; Bennett J
    J Clin Invest; 2011 Jun; 121(6):2160-8. PubMed ID: 21606598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Canine and human visual cortex intact and responsive despite early retinal blindness from RPE65 mutation.
    Aguirre GK; Komáromy AM; Cideciyan AV; Brainard DH; Aleman TS; Roman AJ; Avants BB; Gee JC; Korczykowski M; Hauswirth WW; Acland GM; Aguirre GD; Jacobson SG
    PLoS Med; 2007 Jun; 4(6):e230. PubMed ID: 17594175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results at 5 Years After Gene Therapy for RPE65-Deficient Retinal Dystrophy.
    Pennesi ME; Weleber RG; Yang P; Whitebirch C; Thean B; Flotte TR; Humphries M; Chegarnov E; Beasley KN; Stout JT; Chulay JD
    Hum Gene Ther; 2018 Dec; 29(12):1428-1437. PubMed ID: 29869534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pseudo-fovea formation after gene therapy for RPE65-LCA.
    Cideciyan AV; Aguirre GK; Jacobson SG; Butt OH; Schwartz SB; Swider M; Roman AJ; Sadigh S; Hauswirth WW
    Invest Ophthalmol Vis Sci; 2014 Dec; 56(1):526-37. PubMed ID: 25537204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials.
    Maguire AM; Russell S; Wellman JA; Chung DC; Yu ZF; Tillman A; Wittes J; Pappas J; Elci O; Marshall KA; McCague S; Reichert H; Davis M; Simonelli F; Leroy BP; Wright JF; High KA; Bennett J
    Ophthalmology; 2019 Sep; 126(9):1273-1285. PubMed ID: 31443789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effect of gene therapy on Leber's congenital amaurosis.
    Bainbridge JW; Mehat MS; Sundaram V; Robbie SJ; Barker SE; Ripamonti C; Georgiadis A; Mowat FM; Beattie SG; Gardner PJ; Feathers KL; Luong VA; Yzer S; Balaggan K; Viswanathan A; de Ravel TJ; Casteels I; Holder GE; Tyler N; Fitzke FW; Weleber RG; Nardini M; Moore AT; Thompson DA; Petersen-Jones SM; Michaelides M; van den Born LI; Stockman A; Smith AJ; Rubin G; Ali RR
    N Engl J Med; 2015 May; 372(20):1887-97. PubMed ID: 25938638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Gene therapy for vision restoration in patients with Leber congenital amaurosis (LCA) due to RPE65 gene mutations: beginning the phase IV trial].
    Chacón-Camacho ÓF; Zenteno JC
    Gac Med Mex; 2017; 153(2):276-278. PubMed ID: 28474714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of In Vitro Mutagenesis of RPE65 Protein for Verification of Mutational Pathogenicity Before Gene Therapy.
    Yang U; Gentleman S; Gai X; Gorin MB; Borchert MS; Lee TC; Villanueva A; Koenekoop R; Maguire AM; Bennett J; Redmond TM; Nagiel A
    JAMA Ophthalmol; 2019 Dec; 137(12):1381-1388. PubMed ID: 31580392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Cross-Sectional and Longitudinal Study of Retinal Sensitivity in RPE65-Associated Leber Congenital Amaurosis.
    Kumaran N; Rubin GS; Kalitzeos A; Fujinami K; Bainbridge JWB; Weleber RG; Michaelides M
    Invest Ophthalmol Vis Sci; 2018 Jul; 59(8):3330-3339. PubMed ID: 30025081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement.
    Cideciyan AV; Jacobson SG; Beltran WA; Sumaroka A; Swider M; Iwabe S; Roman AJ; Olivares MB; Schwartz SB; Komáromy AM; Hauswirth WW; Aguirre GD
    Proc Natl Acad Sci U S A; 2013 Feb; 110(6):E517-25. PubMed ID: 23341635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene therapy for RPE65-related retinal disease.
    Miraldi Utz V; Coussa RG; Antaki F; Traboulsi EI
    Ophthalmic Genet; 2018 Dec; 39(6):671-677. PubMed ID: 30335549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical gene therapy for the treatment of RPE65-associated Leber congenital amaurosis.
    Stein L; Roy K; Lei L; Kaushal S
    Expert Opin Biol Ther; 2011 Mar; 11(3):429-39. PubMed ID: 21299439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial.
    Hauswirth WW; Aleman TS; Kaushal S; Cideciyan AV; Schwartz SB; Wang L; Conlon TJ; Boye SL; Flotte TR; Byrne BJ; Jacobson SG
    Hum Gene Ther; 2008 Oct; 19(10):979-90. PubMed ID: 18774912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Status of RPE65 Gene Therapy Trials: Safety and Efficacy.
    Pierce EA; Bennett J
    Cold Spring Harb Perspect Med; 2015 Jan; 5(9):a017285. PubMed ID: 25635059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.